MED1 and prostate carcinoma: MED1 is overexpressed in prostate cancer cells where it acts as an essential coactivator for AR-mediated transcription, and its knockdown results in cell-cycle arrest, decreased proliferation, and increased cell death (96, 97, 98, 99).